within Pharmacolibrary.Drugs.ATC.G;

model G03FB06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 0.025,
    adminDuration  = 600,
    adminMass      = 0.0025,
    adminCount     = 1,
    Vd             = 0.062,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>A combined hormone therapy used primarily for menopausal hormone replacement in women, usually containing medroxyprogesterone acetate and an estrogen (commonly conjugated estrogens or estradiol). Used to treat symptoms associated with menopause such as hot flashes and to prevent osteoporosis. Although still in use, its prescription has declined due to concerns over long-term safety, particularly thromboembolic and cancer risks.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic models for the fixed combination under ATC G03FB06 have been found. Parameter estimates are inferred based on data for individual components (oral medroxyprogesterone acetate and oral estradiol/conjugated estrogen) in healthy adult women.</p><h4>References</h4><ol><li><p>de Lignières, B (1999). Oral micronized progesterone. <i>Clinical therapeutics</i> 21(1) 41–2. DOI:<a href=&quot;https://doi.org/10.1016/S0149-2918(00)88267-3&quot;>10.1016/S0149-2918(00)88267-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10090424/&quot;>https://pubmed.ncbi.nlm.nih.gov/10090424</a></p></li><li><p>Järvinen, A, et al., &amp; Kela, M (2004). Pharmacokinetics of estradiol valerate and medroxyprogesterone acetate in different age groups of postmenopausal women. <i>Maturitas</i> 47(3) 209–217. DOI:<a href=&quot;https://doi.org/10.1016/j.maturitas.2003.01.001&quot;>10.1016/j.maturitas.2003.01.001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15036491/&quot;>https://pubmed.ncbi.nlm.nih.gov/15036491</a></p></li><li><p>Barra, F, et al., &amp; Ferrero, S (2018). Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis. <i>Expert opinion on drug metabolism &amp; toxicology</i> 14(4) 399–415. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2018.1461840&quot;>10.1080/17425255.2018.1461840</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29617576/&quot;>https://pubmed.ncbi.nlm.nih.gov/29617576</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G03FB06;
